For The Maternal RSV Vaccination: Pfizer Requests FDA Approval
A new vaccine developed by Pfizer is showing promising results in the protection of infants against the Respiratory Synciatic Virus (RSV) infection up to the first 6 months of birth. The vaccine is at the last stages of its development and is designed to be administered to the mother during her pregnancy. Pfizer is planning…